Cargando…
Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA
There is a growing number of biomolecules, including peptides, proteins, monoclonal antibodies and RNA, that could be potentially used for the treatment of central nervous system (CNS) diseases. However, the realization of their potential is being hampered by the extraordinary difficulties these com...
Autores principales: | Borrajo, Mireya L., Alonso, María José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888512/ https://www.ncbi.nlm.nih.gov/pubmed/34731414 http://dx.doi.org/10.1007/s13346-021-01086-2 |
Ejemplares similares
-
Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration
por: Wu, Dong-Dong, et al.
Publicado: (2023) -
Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy
por: Khatri, Dharmendra K., et al.
Publicado: (2023) -
Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
por: Chi, Xiao-Kai, et al.
Publicado: (2023) -
Delivering Monoclonal Antibody Infusions to Novel Outpatient Settings
por: Minnich, Amy, et al.
Publicado: (2022) -
Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020)